These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. [Cutaneous effects in hormonal contraception]. Thomas P; Dalle E; Revillon B; Delecour M; Devarenne-nicolle MF; Pagniez I NPN Med; 1985 Jan; 5(81):19-24. PubMed ID: 12281276 [TBL] [Abstract][Full Text] [Related]
9. Physiological estrogen replacement may enhance the effectiveness of the gonadotropin-releasing hormone agonist in the treatment of hirsutism. Carmina E; Janni A; Lobo RA J Clin Endocrinol Metab; 1994 Jan; 78(1):126-30. PubMed ID: 8288696 [TBL] [Abstract][Full Text] [Related]
10. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome. Kazerooni T; Dehghan-Kooshkghazi M Gynecol Endocrinol; 2003 Feb; 17(1):51-6. PubMed ID: 12724019 [TBL] [Abstract][Full Text] [Related]
11. [Acne in adult women: data from a national study on the relationship between type of acne and markers of clinical hyperandrogenism]. Vexiau P; Baspeyras M; Chaspoux C; Foin N; Allaert FA; Abramovici Y Ann Dermatol Venereol; 2002 Feb; 129(2):174-8. PubMed ID: 11937954 [TBL] [Abstract][Full Text] [Related]
12. [FURTHER OBSERVATIONS ON ENDOCRINE ALLERGY IN THE DERMATOLOGICAL FIELD]. BONELLI M; RANTUCCIO F; MENEGHINI CL G Ital Dermatol; 1963; 104():415-22. PubMed ID: 14090675 [No Abstract] [Full Text] [Related]
13. THE NEURODERMATOSIS. HAVYATT M Med J Aust; 1965 Mar; 1(12):419-21. PubMed ID: 14274398 [No Abstract] [Full Text] [Related]
14. Comparison of clinical and laboratory characteristics of cases with polycystic ovarian syndrome based on Rotterdam's criteria and women whose only clinical signs are oligo/anovulation or hirsutism. Hassa H; Tanir HM; Yildiz Z Arch Gynecol Obstet; 2006 Jul; 274(4):227-32. PubMed ID: 16691383 [TBL] [Abstract][Full Text] [Related]
15. A case of estrogen dermatitis. Kim KH; Yoon TJ; Oh CW; Kim TH J Dermatol; 1997 May; 24(5):332-6. PubMed ID: 9198324 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome. Zacchè MM; Caputo L; Filippis S; Zacchè G; Dindelli M; Ferrari A Gynecol Endocrinol; 2009 Aug; 25(8):508-13. PubMed ID: 19551544 [TBL] [Abstract][Full Text] [Related]
17. Acne and hyperandrogenism. Held BL; Nader S; Rodriguez-Rigau LJ; Smith KD; Steinberger E J Am Acad Dermatol; 1984 Feb; 10(2 Pt 1):223-6. PubMed ID: 6232296 [TBL] [Abstract][Full Text] [Related]
18. Estrogen dermatitis: Case report and examination of estrogen receptor-β in the skin. Fukayama M; Asano Y; Shinozaki-Ushiku A; Sato S J Dermatol; 2019 Mar; 46(3):263-266. PubMed ID: 30628111 [TBL] [Abstract][Full Text] [Related]
19. Prevalence of dermatologic manifestations and metabolic biomarkers in women with polycystic ovary syndrome in north China. Feng JG; Guo Y; Ma LA; Xing J; Sun RF; Zhu W J Cosmet Dermatol; 2018 Jun; 17(3):511-517. PubMed ID: 28940857 [TBL] [Abstract][Full Text] [Related]
20. Dermatitis from repeated trauma to the skin. Wilkinson DS Am J Ind Med; 1985; 8(4-5):307-17. PubMed ID: 2933954 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]